SCHEMBL14475241

SCHEMBL14475241

COc1cc(-c2ccc(F)c(F)c2)cc2c(N3CC(OC)C3)nc(-c3cccnc3)nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ GBA1 P04062 3/20 0.40
▸ CHRNB2 P17787 1/20 0.39
▸ CHRNA5 P30532 1/20 0.39
▸ CHRNA4 P43681 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ PDE2A O00408 4/20 0.38
▸ PDE10A Q9Y233 4/20 0.38
▸ PDE5A O76074 3/20 0.38
▸ PDE11A Q9HCR9 3/20 0.38
▸ TTK P33981 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ TLR8 Q9NR97 1/20 0.37
▸ TLR7 Q9NYK1 1/20 0.37
▸ PDE4A P27815 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184060 0.91 MAPT (0.43) MAPTALDH1A1GAAGBA1LMNA
SCHEMBL16184718 0.90 MAPT (0.43) MAPTALDH1A1GAAGBA1LMNA
SCHEMBL16184801 0.90 MAPT (0.44) MAPTALDH1A1GAAGBA1LMNA
SCHEMBL16184051 0.88 MAPT (0.46) MAPTALDH1A1GAAGBA1CHRNB2
SCHEMBL14475253 0.88 MAPT (0.48) MAPTALDH1A1GAAGBA1CHRNB2
SCHEMBL14474741 0.88 MAPT (0.41) MAPTALDH1A1GAAGBA1LMNA
SCHEMBL16184702 0.88 MAPT (0.44) MAPTALDH1A1GAAGBA1LMNA
SCHEMBL16184810 0.88 MAPT (0.50) MAPTALDH1A1GAAGBA1CHRNB2
SCHEMBL16184817 0.88 MAPT (0.49) MAPTALDH1A1GAALMNAKDM4E
SCHEMBL14475243 0.87 MAPT (0.43) MAPTALDH1A1GAACHRNB2CHRNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
WO-2013003586-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB MAPT 509/4885ALDH1A1 1687/4885GAA 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback